Characteristics of acute myeloid leukemia with myelodysplasia‐related changes: A retrospective analysis in a cohort of Chinese patients

• Published in: American journal of hematology Vol. 89; no. 9; pp. 874 - 881
• Main Authors: Xu, Xiao‐Qian, Wang, Jian‐Min, Gao, Lei, Qiu, Hui‐Ying, Chen, Li, Jia, Lin, Hu, Xiao‐Xia, Yang, Jian‐Min, Ni, Xiong, Chen, Jie, Lü, Shu‐Qing, Zhang, Wei‐Ping, Song, Xian‐Min
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2014
• Subjects: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Marrow - pathology; CCAAT-Enhancer-Binding Proteins - genetics; China; Cohort Studies; Cytogenetic Analysis; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3 - genetics; Hematology; Humans; Karyotype; Leukemia, Myeloid, Acute - complications; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - mortality; Male; Middle Aged; Multivariate Analysis; Mutation; Myelodysplastic Syndromes - complications; Myelodysplastic Syndromes - diagnosis; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - mortality; Nuclear Proteins - genetics; Retrospective Studies; Young Adult; China
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.23772

We retrospectively analyzed 449 patients with AML under the WHO classification of AML 2008 and probed implications of this classification in diagnosis and treatment of acute myeloid leukemia with myelodysplasia‐related changes (AML‐MRC) among them. The clinical presentations, biological features, treatments, and prognosis of patients diagnosed with AML‐MRC were analyzed and compared with those of AML not otherwise specified (AML‐NOS). In all patients, 115 (25.6%) were diagnosed as AML‐MRC including 64 males and 51 females with median onset age of 48 years (range from 17 to 78). Their complete remission (CR) rate was 60.9% and relapse rate was 57.1%. The observed median overall survival (OS) and disease‐free survival (DFS) were 10 and 5 months, respectively, which was significantly shorter than those of AML‐NOS patients (P < 0.05). The prognosis of AML‐MRC patients with myelodysplastic syndrome (MDS)‐related cytogenetics sole was similar to those with history of MDS or myelodysplastic/myeloproliferative neoplasm (MDS/MPN). Patients with MDS‐related cytogenetic abnormalities and/or history of MDS or MDS/MPN predisposed significantly shortened CR, OS, and DFS than AML‐MRC patients with only multilineage dysplasia (MLD) and AML‐NOS patients (P < 0.05). Multivariate analysis showed that age, cytogenetics, and history of MDS or MDS/MPN were independent prognostic factors. Patient diagnosed as AML‐MRC presented distinctive clinical and biological features. Presence of MLD does not change the prognosis. Am. J. Hematol. 89:874–881, 2014. © 2014 Wiley Periodicals, Inc.